FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, even
though it induces significant adverse effects. Several institutions have begun using modified …

PURPOSE Pegylated recombinant human hyaluronidase (PEGPH20) degrades hyaluronan
(HA) and, in combination with chemotherapy, prolongs survival in preclinical models. The …

Simple Summary Metastatic PC often represents a complex decision-making moment for
oncologists, particularly due to the general conditions of the patients, age, and the potential …

Background Pancreatic cancer statistics are dismal, with a 5-year survival of less than 10%,
and more than 50% of patients presenting with metastatic disease. Metabolic …

Abstract Purpose FOLFIRINOX (FFN), nab-paclitaxel plus gemcitabine (GN), and
gemcitabine are three systemic therapies that provide clinically meaningful benefit to …

The introduction of the FOLFIRINOX regimen within the last decade marked the first
progress in the clinical field of metastatic pancreatic cancer which had not seen any …

Pancreatic cancer (PC) incidence rates are rapidly increasing in developed countries, with
half the patients being metastatic at diagnosis. For decades, fluorouracil, then gemcitabine …

Background The prognosis of pancreatic cancer (PC) has been improved by new
chemotherapy regimens (combination of 5-fluorouracil, oxaliplatin, irinotecan, and …

Oxaliplatin resistance limits its effectiveness in the treatment of hepatocellular carcinoma
(HCC). Abnormal activation of the PI3K/AKT/mTOR pathway has been associated with …

Currently, the combination of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin
(FOLFIRINOX) is the standard therapy for metastatic pancreatic cancer. In recent years …